Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
30 pending office actions • 21 art units • 25 examiners • 0 of 30 (0%) have an AI response strategy ready • 22 patents granted in the last 365 days
University Health Network has 30 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 25 examiners and 21 art units, indicating substantial distribution across both examination personnel and technical groups. The lower examiner and art-unit counts relative to pending matters show that some assignments contain multiple matters.
AKAR, SERKAN is the busiest examiner, with 5 pending matters. That concentration makes the examiner a specific point for reviewing recurring objections, interview opportunities, and response timing across related matters.
The 21 art units still create a significant coordination burden. Counsel should centralize issue tracking while separating technical positions by art unit and preserving matter-specific analysis for examiner practice.
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (17%) |
| §103 only | 6 (20%) |
| §112 only | 4 (13%) |
| Double-patenting only | 2 (7%) |
| Double-patenting + other | 4 (13%) |
| Multi-statute (no §101) | 8 (27%) |
| No statute on record | 1 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AKAR, SERKAN | 5 | 66.0% | +34.6% |
| STAVROU, CONSTANTINA E | 2 | 42.4% | +35.6% |
| TALUKDER, MD K | 1 | 80.1% | +14.1% |
| CHNG, JOY POH AI | 1 | 60.6% | +19.0% |
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| ABBAS, SYED JARAR | 1 | 25.0% | +0.0% |
| WILSON, JERICA KATLYNN | 1 | 60.5% | +39.8% |
| FONTAINHAS, AURORA M | 1 | 37.8% | +49.4% |
| MOSHER, ERIC PARKER | 1 | 100.0% | +0.0% |
| UNDERDAHL, THANE E | 1 | 58.8% | +50.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18578888 | PORPHYRIN NANOVESICLE WITH FATTY ACID CONJUGATE | MOSHER, ERIC PARKER | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044288 | METHODS FOR GENERATING NEURAL PROGENITOR CELLS WITH A SPINAL CORD IDENTITY | CONNORS, ALEXANDRA F | 45d overdue |
| 18008053 | IMMUNOGENIC RETROELEMENTS AND THEIR USE IN CANCER THERAPY | JOHANNSEN, DIANA B | 4d overdue |
| 18662583 | PORTABLE IMAGING DEVICES AND SYSTEMS FOR REAL-TIME VISUALIZATION OF BACTERIA AND RELATED METHODS | AKAR, SERKAN | 8d |
| 17631820 | MHC CLASS II MOLECULES AND METHODS OF USE THEREOF | D' AMBROSIO, THEA | 22d |
| 17620103 | FUROSEMIDE ANALOGUES AND COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ALZHEIMER'S DISEASE | CHENG, KAREN | 23d |
| 18899233 | NEUROTECHNOLOGY SYSTEM AND METHOD FOR MONITORING SEIZURE DEVELOPMENT AND ASSESSING ANTI-SEIZURE DRUG RESPONSE | CHNG, JOY POH AI | — |
| 18699121 | MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF | ABBAS, SYED JARAR | — |
| 18684053 | METHODS AND COMPOSITIONS FOR TREATING ALPHA-SYNUCLEIN-MEDIATED NEURODEGENERATION | WILSON, JERICA KATLYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18023289 | COMPOSITIONS AND METHODS FOR GENERATING HUMAN YOLK SAC-LIKE HEMATOPOIETIC CELLS | STAVROU, CONSTANTINA E | 31d overdue |
| 18662583 | PORTABLE IMAGING DEVICES AND SYSTEMS FOR REAL-TIME VISUALIZATION OF BACTERIA AND RELATED METHODS | AKAR, SERKAN | 8d |
| 19025446 | PORTABLE IMAGING DEVICES, METHODS, AND SYSTEMS FOR WOUND IMAGING AND MONITORING | AKAR, SERKAN | 82d |
| 19081680 | METHOD AND SYSTEM FOR FLUORESCENCE IMAGING AND COLLECTION OF DATA FOR DIAGNOSTIC PURPOSES | AKAR, SERKAN | — |
| 19025038 | PORTABLE IMAGING DEVICES, METHODS, AND SYSTEMS FOR WOUND IMAGING AND MONITORING | AKAR, SERKAN | — |
| 18943247 | SYSTEMS, METHODS, AND DEVICES FOR THREE-DIMENSIONAL IMAGING, MEASUREMENT, AND DISPLAY OF WOUNDS AND TISSUE SPECIMENS | TALUKDER, MD K | — |
| 18899233 | NEUROTECHNOLOGY SYSTEM AND METHOD FOR MONITORING SEIZURE DEVELOPMENT AND ASSESSING ANTI-SEIZURE DRUG RESPONSE | CHNG, JOY POH AI | — |
| 18684053 | METHODS AND COMPOSITIONS FOR TREATING ALPHA-SYNUCLEIN-MEDIATED NEURODEGENERATION | WILSON, JERICA KATLYNN | — |
| Art Unit | Apps |
|---|---|
| 3797 | 5 |
| 1675 | 3 |
| 1674 | 2 |
| 1654 | 2 |
| 1632 | 2 |
| 2648 | 1 |
| 3686 | 1 |
| 1691 | 1 |
| 1621 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19081680 | METHOD AND SYSTEM FOR FLUORESCENCE IMAGING AND COLLECTION OF DATA FOR DIAGNOSTIC PURPOSES | AKAR, SERKAN | 3797 | §103 | Non-Final OA | — | Pending | Mar 17, 2025 |
| 19025446 | PORTABLE IMAGING DEVICES, METHODS, AND SYSTEMS FOR WOUND IMAGING AND MONITORING | AKAR, SERKAN | 3797 | DP | Final Rejection | 82d | Pending | Jan 16, 2025 |
| 19025038 | PORTABLE IMAGING DEVICES, METHODS, AND SYSTEMS FOR WOUND IMAGING AND MONITORING | AKAR, SERKAN | 3797 | §112 | Non-Final OA | — | Pending | Jan 16, 2025 |
| 18943247 | SYSTEMS, METHODS, AND DEVICES FOR THREE-DIMENSIONAL IMAGING, MEASUREMENT, AND DISPLAY OF WOUNDS AND TISSUE SPECIMENS | TALUKDER, MD K | 2648 | Other | Non-Final OA | — | Pending | Nov 11, 2024 |
| 18899233 | NEUROTECHNOLOGY SYSTEM AND METHOD FOR MONITORING SEIZURE DEVELOPMENT AND ASSESSING ANTI-SEIZURE DRUG RESPONSE | CHNG, JOY POH AI | 3686 | §101§112 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18723094 | TREATMENT FOR ACUTE MYELOID LEUKEMIA OR LYMPHOMA | SHIAO, REI TSANG | 1691 | DP | Final Rejection | — | Pending | Jun 21, 2024 |
| 18662583 | PORTABLE IMAGING DEVICES AND SYSTEMS FOR REAL-TIME VISUALIZATION OF BACTERIA AND RELATED METHODS | AKAR, SERKAN | 3797 | §103§112 | Final Rejection | 8d | Pending | May 13, 2024 |
| 18699121 | MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF | ABBAS, SYED JARAR | 1674 | §102§112DP | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18684053 | METHODS AND COMPOSITIONS FOR TREATING ALPHA-SYNUCLEIN-MEDIATED NEURODEGENERATION | WILSON, JERICA KATLYNN | 1621 | §102§103 | Final Rejection | — | Pending | Feb 15, 2024 |
| 18414178 | ANTI-TRANSTHYRETIN ANTIBODIES | FONTAINHAS, AURORA M | 1675 | §112DP | Final Rejection | — | Pending | Jan 16, 2024 |
| 18578888 | PORPHYRIN NANOVESICLE WITH FATTY ACID CONJUGATE | MOSHER, ERIC PARKER | 1612 | §103§112DP | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18569063 | CARDIOMYOCYTE SUBTYPES AND METHODS OF MAKING AND USING | UNDERDAHL, THANE E | 1699 | §101§102§103DPOther | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18288241 | MODIFIED ORGANS AND TISSUES | CHASE, CAROL ANN | 1646 | §102§103§112 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18555339 | POINT-OF-CARE PREDICTION OF MUSCLE RESPONSIVENESS TO THERAPY DURING NEUROREHABILITATION | AGAHI, PUYA | 3791 | §103§112 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18263658 | IMPROVED T-CELLS FOR CANCER THERAPY USING AMINO ACID STARVATION PATHWAYS | JUEDES, AMY E | 1644 | §102§103§112 | Non-Final OA | — | Pending | Jul 31, 2023 |
| 18255136 | METHODS AND USES FOR NDFIP1 FUSION POLYPEPTIDES IN TREATING NEURODEGENERATIVE DISEASES, BRAIN AND/OR TRAUMATIC AND NON-TRAUMATIC SPINAL CORD INJURIES, AND/OR OPTIC NEUROPATHIES | HELLMAN, KRISTINA M | 1654 | §103§112 | Non-Final OA | — | Pending | May 31, 2023 |
| 18044288 | METHODS FOR GENERATING NEURAL PROGENITOR CELLS WITH A SPINAL CORD IDENTITY | CONNORS, ALEXANDRA F | 1634 | §103§112 | Final Rejection | 45d overdue | Pending | Mar 07, 2023 |
| 18023289 | COMPOSITIONS AND METHODS FOR GENERATING HUMAN YOLK SAC-LIKE HEMATOPOIETIC CELLS | STAVROU, CONSTANTINA E | 1632 | §103 | Final Rejection | 31d overdue | Pending | Feb 24, 2023 |
| 18067318 | CIRCULATING CARDIOVASCULAR BIOMARKERS AND VASCULAR STABILIZING THERAPY | SCHWECHTER, BRANDON ROSS | 1674 | §101§102§103§112 | Final Rejection | — | Pending | Dec 16, 2022 |
| 18008053 | IMMUNOGENIC RETROELEMENTS AND THEIR USE IN CANCER THERAPY | JOHANNSEN, DIANA B | 1682 | §101§102§103§112 | Non-Final OA | 4d overdue | Pending | Dec 02, 2022 |
| 17911208 | BIOMARKERS FOR DETECTING OF OUTCOME/RISK OF THE PATIENTS WITH A RESPIRATORY ILLNESS | CHERNYSHEV, OLGA N | 1675 | §112 | Non-Final OA | — | Pending | Sep 13, 2022 |
| 17744483 | SCREW-IN BIPOLAR ABLATION, MAPPING AND THERAPEUTIC CATHETER | HADDAD, MOUSSA MAHER | 3796 | §103 | Final Rejection | 22d | Pending | May 13, 2022 |
| 17642640 | DETECTION OF CIRCULATING TUMOR DNA USING DOUBLE STRANDED HYBRID CAPTURE | CASH, KAILEY ELIZABETH | 1683 | §103 | Non-Final OA | 22d | Pending | Mar 11, 2022 |
| 17631820 | MHC CLASS II MOLECULES AND METHODS OF USE THEREOF | D' AMBROSIO, THEA | 1654 | §101§103§112Other | Final Rejection | 22d | Pending | Jan 31, 2022 |
| 17620103 | FUROSEMIDE ANALOGUES AND COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ALZHEIMER'S DISEASE | CHENG, KAREN | 1623 | §102§112 | Non-Final OA | 23d | Pending | Dec 16, 2021 |
| 17616522 | METHODS OF MAKING AND USING LIVER CELLS | RAHMAN, MASUDUR | 1633 | §112 | Final Rejection | — | Pending | Dec 03, 2021 |
| 17509914 | METHOD AND SYSTEM FOR IMAGING AND COLLECTION OF DATA FOR DIAGNOSTIC PURPOSES | AKAR, SERKAN | 3797 | §112 | Non-Final OA | — | Pending | Oct 25, 2021 |
| 17413772 | BIOMARKER COMBINATIONS IN EX VIVO LUNG PERFUSION (EVLP) PERFUSATE | BORGEEST, CHRISTINA M | 1675 | §112DP | Final Rejection | — | Pending | Jun 14, 2021 |
| 17057130 | METHODS AND COMPOSITIONS COMPRISING TANKYRASE INHIBITORS FOR GENERATING INSULIN PRODUCING CELLS | STAVROU, CONSTANTINA E | 1632 | §103 | Final Rejection | — | Pending | Nov 20, 2020 |
| 16966293 | DEVICES, SYSTEMS, AND METHODS FOR TUMOR VISUALIZATION AND REMOVAL | RAYMOND, KEITH MICHAEL | 3798 | §103 | Final Rejection | 29d | Pending | Jul 30, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversity Health Network has 30 pending office actions as of October 2026, spread across 21 art units and 25 examiners.
Serkan Akar has the most, with 5 of University Health Network's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
